Abstract
Introduction
Sudden cardiac death (SCD), defined as a "death occurring within 1 hour from the onset of symptoms in someone without a previously recognized cardiovascular abnormality" [1, 2] , remains one of the leading causes of death in developed countries [3] . Many cardiac defects, which may cause SCD, can be noninvasively identified by analyzing the electrocardiogram (ECG), which is the recording of the electrical activity of the heart, and the heart-rate (HR) signal (HRS), which is the sequence of the reciprocal of the cardiac-period represented as function of time. Indeed, abnormalities in cardiac repolarization, identifiable by analyzing the electrocardiographic ST segment and T wave [4] [5] [6] , are also known to be linked to an increased risk of developing malignant ventricular arrhythmias that may degenerate in SCD [7] [8] [9] ; and mean HR (MHR) and HR variability (HRV) parameters, obtained by analyzing the HRS, are universally recognized as indicators of SCD [10, 11] . Monitoring of repolarization and HR indexes is usually performed by medical evaluation of standard ECG tracings or Holter ECG recordings, which require the subject to visit hospitals or doctor offices [12] [13] [14] . In case of transient abnormal cardiac episodes, such recordings may likely not include them.
Recently, wearable physical activity monitoring devices (such as heart-rate monitoring system, accelerometers, pedometers, and multiple-sensor devices) have become very popular among athletes for training optimization. In particular, cardiac monitoring devices are typically used for training optimization in terms of intensity, volume, duration and frequency. They usually measure instantaneous HR and sometimes record HRS. Occasionally, the most sophisticate devices also record and memorize ECG. Thus, the acquired data are the same that may be used for cardiac risk assessment. Consequently, if clinically reliable HRS and ECG are provided, such sensors could be used to gain important for cardiac risk evaluation not only in athletes [15] [16] [17] [18] but in the general population, who could comfortably wears these devises at home, during daily activities or when feeling sick. The BioHarness 3.0 (BH3) by Zephyr is a popular wearable system specifically designed for training optimization of professional athletes. BH3 acquires several biological data among which the ECG and HRS. Thus, aim of the present study (which is part of larger project on BH3 validation) is to evaluate the reliability of HRS_BH3 in order to gain information on the possibility of using BH3 in the general population for contributing to the assessment of the risk of SCD.
Methods

Zephyr BioHarness 3.0
BH3 is a physiological monitoring telemetry device developed by Zephyr (www.zephyranywhere.com), now part of Medtronic. BH3 consists of a chest strap and an electronics module that attaches to the strap. The device may transmit by radio-frequency (transmission mode) or stores (logging mode) the data. While the first allows the live viewing of data; the second modality allows the later download of data. Among the output biological signals, there are ECG and HRS. Particularly, the single-lead ECG tracing (ECG_BH3; mV) is sampled at 250 Hz, and HRS signal (HRS_BH3; bpm) is sampled at 1 Hz.
Data acquisition
Clinical data were acquired from 10 healthy subjects (age: 34±17 years) in order to have some levels of HRV. After wearing BH3 and set the device in logging mode, each subject was asked to stay still to acquire the signals in resting conditions. Eventually, ECG_BH3 and HRS_BH3 were downloaded on a PC for subsequent processing.
Signal processing
The tachogram is a signal defined as the RR-interval sequence expressed in function of consecutive number of beats (or time by multiplying by the mean RR interval). Since the tachogram represents the standard signal for studying HR and HRV, ECG_BH3 was elaborated in order to get the tachogram (HRS_TG), which is eventually compared to HRS_BH3. Particularly, ECG_BH3 was processed to detect the R-peak sequence using the Pan-Tompkins algorithm [19] . By considering the relation that exists between instantaneous HR and RR interval, the following equation 
is used to compute the HR sequence from the RR sequence.
All processing procedures were implemented in MATLAB.
Signal comparison
Comparison between HRS_BH3 and HRS_TG was accomplished in terms of mean HR (MHR, bpm) 
Results
An example of qualitative results is reported in Fig.1  that shows HRS_BH3 and HRS_TG signals of subject n. 2. Although HRS_TG and HRS_BH3 follow the same trend, HRS_TG is characterized by higher and more frequent amplitude variations (higher high-frequency content).
The quantitative results relative to each individual are reported in Table 1 
Discussion
The work presented in this paper, which represents the first part of larger project on BH3 validation, is finalized to evaluate reliability of cardiac signals provided by BH3 in order to gain information on the possibility of using BH3 in the general population for contributing to the assessment of the risk of SCD. To this aim, ECG_BH3 was elaborated in order to get HRS_TG, which is eventually compared to HRS_BH3, this latter signal being the one to be evaluated. Compared to HRS_TG, HRS_BH3 shows much lower amplitude deviations. A possible cause of this discrepancy could be the 1 Hz resampling procedure necessarily performed to get HRS_BH3 since HRS_TG is by definition sampled at a frequency that corresponds to the subject's MHR (on average 73 bpm and thus 1.2 Hz). Another possible cause of discrepancy between HRS_BH3 and HRS_TG could While the correctness of R-peak positions (detected from ECG_BH3) was visually checked, the same cannot be done with the R peaks detected by BH3 because such data is not available. If there are differences in R-peak detection, these differences will be reflected in HR calculation. According to our results, HRS_BH3 provides reliable MHR estimations (i.e. comparable to those calculated from HRS_TG) but not HRV values (here measured as HRSD) which is significantly underestimated. Moreover, the underestimation level is strongly correlated to the amount of the variability. Therefore, to light of results, the use of HRS_BH3 is appropriate for sport applications relying on MHR estimations, but not to clinical evaluations based on HRV measurements. Instead, ECG_BH3, although sampled at a frequency (200 Hz) that is lower than that characterizing modern ECG machine (typically over 1000 Hz), can provide useful clinical information, allowing computation of both HR and repolarization parameters such as QT interval [20] Twave alternans [21, 22] and f99 [23] . Still, there are several important differences between BH3 and traditional clinical ECG devices. First of all, the latter provides only one lead ECG whereas the former provide at least 12-lead ECG, and repolarization indexes are known to be lead-dependent [24, 25] . In addition, for the way it has been acquired, ECG_BH3 is likely a very noisy recording, so that efficient filtering procedures [26, 27] should be applied before computing repolarization parameters [28] . Despite these limitations, ECG_BH3 still provide precious information that could join (not replace) those from traditional electrocardiography in order to improve identification of subjects at increased risk of SCD in the general population.
5.
Conclusions
BH3 is a wearable sensor that provides ECG_BH3 and HRS_BH3.
If ECG_BH3 may found some complementary clinical utility when fighting SCD in the general population, HRS_BH3 is indicated only for sport applications based on MHR estimations, since HRV measurements were not found to be reliable.
